🇺🇸 Azd5363 in United States

15 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Hypokalaemia — 3 reports (20%)
  2. Sinus Bradycardia — 3 reports (20%)
  3. Sinus Arrhythmia — 2 reports (13.33%)
  4. Acute Hepatic Failure — 1 report (6.67%)
  5. Anaemia — 1 report (6.67%)
  6. Disease Progression — 1 report (6.67%)
  7. Facial Nerve Disorder — 1 report (6.67%)
  8. Haematemesis — 1 report (6.67%)
  9. Hypercalcaemia — 1 report (6.67%)
  10. Hypersensitivity — 1 report (6.67%)

Source database →

Azd5363 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in United States

Frequently asked questions

Is Azd5363 approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Azd5363 in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.